Vaxart (VXRT) said an agreement with Advanced Technology International on a COVID-19 vaccine candidate study was amended with an increase of $4.6 million in the total estimated ceiling for funding to $460.7 million.
The project agreement in June covered funding for a comparative study to evaluate the company's oral pill XBB COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the US Food and Drug Administration, Vaxart said Friday in a regulatory filing.
The amendment boosted the funding allotted to the phase 2b trial by $37.7 million to $134.2 million available for payment, Vaxart said.
Advanced Technology International is a consortium management firm funded by the US Department of Health and Human Services' Biomedical Advanced Research and
Development Authority.
Price: 0.66, Change: +0.05, Percent Change: +8.59
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。